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Objectives:
 
 Recently published studies have demonstrated
increased efficacy and cost-effectiveness of combination
 
therapy with interferon and 
 

 
-2b/ribavirin compared with
interferon-alpha monotherapy in the treatment of chronic
hepatitis C (CHC). Combination therapy is associated with
 
a clinically important adverse effect: ribavirin-induced
hemolytic anemia (RIHA). The objective of this study was
to evaluate the direct health-care costs and management of
RIHA during treatment of CHC in a clinical trial setting.
 
Methods:
 
 A systematic literature review was conducted
to synthesize information on the incidence and manage-
ment of RIHA. Decision-analytic techniques were used
to estimate the cost of treating RIHA. Uncertainty was
evaluated using sensitivity analyses.
 
Results: 
 
RIHA, defined as a reduction in hemoglobin to
less than 100 g/L, occurs in approximately 7% to 9%
of patients treated with combination therapy. The stan-
dard of care for management of RIHA is reduction or
discontinuation of the ribavirin dosage. We estimated
the direct cost of treating clinically significant RIHA to
be $170 per patient receiving combination therapy per
48-week treatment course (range $68–$692). The results
of the one-way sensitivity analyses ranged from $57 to
$317. In comparison, the cost of 48 weeks of combina-
tion therapy is $16,459.
 
Conclusions: 
 
The direct cost of treating clinically signif-
icant RIHA is 1% ($170/$16,459) of drug treatment
costs. Questions remain about the optimal dose of rib-
avirin and the incidence of RIHA in a real-world popu-
lation. Despite these uncertainties, this initial evalua-
tion of the direct cost of treating RIHA provides an
estimate of the cost and management implications of
this clinically important adverse effect.
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Introduction
 
It is estimated that up to 80% of individuals ex-
posed to hepatitis C virus develop chronic infec-
tion [1]. Worldwide prevalence rates of chronic
hepatitis C (CHC) range from 0.3% in Australia
to 14.5% in Egypt, and the hepatitis C virus in-
fects over 170 million people worldwide [2]. The
prevalence rate in the US population is 1.8%, cor-
responding to a caseload of almost 4 million indi-
viduals [3]. Progression to cirrhosis and end-stage
liver disease occurs in many patients, resulting in
significant morbidity from the complications of de-
compensated disease, including variceal bleeding,
hepatic encephalopathy, and ascites [4]. Further-
more, CHC is the leading indication for liver
transplantation in the United States [5].
Until recently, interferon-alpha has been the main-
stay of therapy [6]. However, sustained biochemi-
cal and virologic responses are uncommon with
interferon-alpha monotherapy [7,8]. Combination
therapy with interferon 
 

 
-2b and ribavirin has in-
creased the rate of sustained biochemical, viro-
logic, and histologic responses to initial therapy and
after relapse following interferon-alpha monother-
apy. Only 15% to 20% of treatment-naïve patients
with CHC have a sustained virologic response to
interferon-alpha monotherapy when measured 24
weeks after treatment. Combination therapy has
increased the sustained virologic response to 35%
to 43% 24 weeks after discontinuation of a 24-
week course of therapy [9]. This combination has
recently been approved in the United States for
treatment of both initial infection and relapse [9–
11]. The major dose-limiting toxicity of ribavirin
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is reversible hemolytic anemia. A mean maximum
decrease in hemoglobin of 29 to 31 g/L was observed
in clinical trials [12], with hemoglobin values of less
than 100 g/L in approximately 7% to 9% of patients
[9–11].
Ribavirin-induced hemolytic anemia (RIHA) is
typically managed with reduction or discontinua-
tion of the ribavirin dosage, but transfusion of
packed red blood cells is occasionally necessary in
cases of severe or symptomatic anemia [13]. Some
clinicians are exploring the use of the erythroid
blood progenitor precursor epoetin for the treat-
ment of RIHA, primarily in patients undergoing
liver transplants [14–17].
The purpose of this study is to analyze the di-
rect health-care costs associated with the treat-
ment of clinically significant RIHA in the context
of overall drug-therapy costs. Management strate-
gies for minimizing this adverse effect are also dis-
cussed, including treating RIHA with epoetin. Un-
certainty in the incidence of RIHA in a real-world
setting underscores the importance of RIHA as an
adverse effect of clinical concern.
 
Methods
 
Literature Review
 
We performed a systematic literature review to as-
sess the incidence and treatment of RIHA. We
searched the MEDLINE database from 1991 through
August 1999 using the key words 
 
hepatitis C, inter-
feron
 
, and 
 
ribavirin.
 
 In an effort to capture more re-
cent information on RIHA, we conducted a focused
search of MEDLINE, the Drugs and Pharmacology
Database (EMBASE), and International Pharma-
ceutical Abstracts (IPA) for 1996 through August
1999, using the search term 
 
ribavirin-induced
hemolytic anemia.
 
 Thirty English-language stud-
ies, abstracts, and review articles were found. Ref-
erences cited in relevant articles from this initial
bibliography were reviewed for additional studies.
All studies were reviewed for inclusion in the anal-
ysis. Studies involving treatment with ribavirin
monotherapy, or interferon 
 

 
-2b and ribavirin
combination therapy that included incidence and
treatment of adverse effects, were included in
the study. Case reports, abstracts with insufficient
data on the incidence of RIHA, and early versions
of subsequently published reports were excluded.
The selected studies were grouped according to
the number of patients included in the studies, pa-
tient characteristics, and treatment regimens, re-
sulting in seven distinct groupings of trials [9–11,14–
36] (Table 1).
 
Model Description
 
Using decision-analytic techniques, a model (Fig.
1) was constructed to estimate the incidence and
costs of RIHA. The model represents a cohort of
patients with CHC receiving interferon 
 

 
-2b/rib-
avirin therapy for a 48-week treatment course. Pa-
tients with decompensated cirrhosis and underly-
ing hemolysis were excluded from the model.
Because RIHA usually appears within 2 to 4
weeks of initiation of therapy [13], the branches
of the model where the dose of ribavirin was re-
duced or the drug discontinued included only 4
weeks of combination therapy. Patients in whom
ribavirin was discontinued completed the remain-
der of the treatment course with interferon-alpha
therapy only. The current clinical standard of care
for dosage reduction, a 50% reduction in the rib-
avirin dosage, was assumed [13].
 
Likelihood of Events
 
Data from three large, randomized trials were
used to estimate the probability in the base case
[9–11]. The percentage of patients requiring dos-
 
Table 1
 
Groups of trials used in model
 
No. study patients
(Total Rb)
Percent of ribavirin patients
Trial group [references] Rb dose reduction (%) Rb discontinued (%) Transfusions (%) Epoetin (%)
Rb monotherapy [18–23] 268 (171) 7.0 2.3 0.6 Not used in trials
IFN/Rb therapy
(
 

 
 50 patients) [24–30] 242 (194) 12.9 3.1 0 Not used in trials
OLT [14–16] 59 (45) 22.2 20.0 6.7 11.0
Epoetin abstract [17] 47 (47) 21.3 4.3 0 36.2
IFN/Rb therapy 782 (399) 5.0 1.3 0.8 Not used in trials
(
 

 
 50 patients) [31–35]
European meta-analysis [36] 186 (78) 0 3.8 0 Not used in trials
Weighted average 1316 (763) 8.5 3.1 - -
Phase III trials [9–11] 2089 (1184) 7.4 0.3 0.1 Not used in trials
 
IFN, interferon-alpha; OLT, orthotopic liver transplant, Rb, ribavirin.
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age reduction, or in whom ribavirin was discon-
tinued, or who required transfusions or adminis-
tration of epoetin, were obtained from these trials
and verified with a review of the data prepared by
Maddrey [12]. Because definitions of clinically sig-
nificant hemolytic anemia and mild, moderate,
and severe anemia were not available in the litera-
ture, these categories were extrapolated using the
absolute hemoglobin reductions published by Mad-
drey [12]. The mean reduction in hemoglobin from
baseline in the trials was 29 to 31 g/L. Based on Mad-
drey’s work, we designated an absolute decrease in
hemoglobin of greater than 20 g/L as clinically signif-
icant. Accordingly, we defined mild hemolytic ane-
mia as an absolute decrease of 20 to 30 g/L, a moder-
ate decrease between 30 and 40 g/L, and a severe
decrease as greater than 40 g/L. Transfusions were
used in only 0.1% of the patients in these trials, and
only in the patients in whom the drug was discon-
tinued. This percentage was divided equally be-
tween patients experiencing moderate or severe
anemia and those who subsequently discontinued
ribavirin as represented in the decision-tree model
of RIHA in Figure 1. Epoetin was not used in the
phase III trials and thus was not included in the
base case [9–11]. The probabilities for the base
case are listed in Table 2.
 
Unit Costs and Frequency Parameters
 
The average wholesale prices obtained from the
1999 
 
Drug Topics Red Book
 
 were used to estab-
lish medication costs for the base case [37]. Costs
from an online retailer of pharmaceuticals were
utilized to obtain a range for the sensitivity analy-
ses [38]. Laboratory costs, clinic visit costs, and
infusion center administration costs for 1995 were
obtained from a large, private, health insurer data-
base for the state of Washington. These were up-
dated to 1999 figures using the US consumer price
index for medical care. The average cost of the
transfusion of one unit of packed red blood cells,
including laboratory, processing, and administra-
tive costs, was obtained from the Puget Sound
Blood Center and University of Washington Med-
ical Center. The unit costs for the base case are
listed in Table 3. Frequency of laboratory draws
Figure 1 Model of ribavirin-induced homolytic anemia. Epo,
epoetin; Hg, hemoglobin; Rb, ribavirin; Transf, transfusion.
 
Table 2
 
Probabilities used in the model
 
Probability parameter Base case value (range) Reference (reference for range)
Developing clinically significant hemolytic anemia 0.74 (0.37–1) 12
Developing not clinically significant hemolytic anemia 0.26 (0.63–0) 12
Developing mild hemolytic anemia, given development 
of clinically significant anemia
0.41 (0.72–0.11) 12
Developing moderate hemolytic anemia, given development 
of clinically significant anemia
0.37 (0.19–0.56) 12
Developing severe hemolytic anemia, given development 
of clinically significant anemia 
0.22 (0.11–0.33) 12
No change in dose will be required, given moderate anemia 0.92 (0.95–0.89) 9–11
Dosage reduction will be required, given moderate anemia 0.074 (0.05–0.085) 9–11 (31–35,24–36)
Ribavirin discontinuation will be required, given moderate anemia 0.003 (0–0.031) 9–11 (24–36)
Dosage reduction will be required, given severe anemia 0.75 (0.87–0.5) 9–11
Ribavirin discontinuation will be required, given severe anemia 0.25 (0.13–0.5) 9–11
No epoetin and no transfusions 0.9995–1 (0.723–1) 9–11
Receiving epoetin 0 (0–0.11) 9–11 (14–16))
Receiving transfusion 0–0.0005 (0–0.067) 9–11 (14–16)
Receiving epoetin and transfusion 0 (0–0.1) 9–11 (14–16)
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and clinic visits was taken from the clinical trials,
whereas frequency of transfusions and of visits to
the blood center were clinical estimates [9–11].
The duration of epoetin therapy was taken from a
standard drug therapy [39]. These parameters are
all listed in Table 3.
 
Outcome Assessment–Base Case
 
The primary outcome was the direct medical cost
of treating clinically significant RIHA. The cost
was determined by subtracting the direct costs of
monitoring for RIHA in the population in whom
it was not clinically significant from the costs of
treating RIHA in the population in whom it was
determined to be clinically significant.
 
Sensitivity Analyses
 
We performed a one-way sensitivity analysis on
each probability and cost parameter, the frequency
of laboratory draws and clinic visits, and the epoe-
tin dose and duration of therapy. Each parameter
was varied individually while the others were held
constant. We relied on the inclusion of additional
studies in the data set to determine the range used
for the probabilities [24–36]. When literature esti-
mates were not available for probabilities, and
when estimating the ranges for frequencies and
costs, we assumed a decrease of 50% and an in-
crease of 50% to 100%. These assumptions were
based on clinical judgment and the desire to pro-
vide a conservative estimate that would yield a ro-
bust model. The probability ranges are provided
in Table 2.
We also conducted analyses of best- and worst-
case scenarios. The probabilities used in these anal-
yses are also given in Table 2. Probabilities from
additional studies in the data set were incorporated
into these models. For example, in the best-case
scenario, the percentage of patients in the combina-
tion arm who experienced moderate RIHA requir-
ing dose reduction was taken from the combina-
tion of all trials enrolling more than 50 patients,
or 5.0% (Table 1, Group 5). Other parameters
were varied as outlined above.
In the worst-case scenario, we pooled the data
from 763 ribavirin patients (Groups 2 through 6
in Table 1), and used the weighted averages of
8.5% and 3.1% as the probabilities of developing
moderate RIHA requiring dosage reduction or dis-
continuation, respectively. Probabilities for the de-
velopment of clinically significant hemolytic ane-
mia, of moderate or severe anemia, of severe anemia
requiring ribavirin discontinuation, and costs made
use of assumptions previously outlined. Probabilities
in the branches outlining the use of epoetin and trans-
fusions were based on a study population of recur-
rent hepatitis C patients following orthotopic liver
transplant (OLT) (Table 1, Group 3). Use of epoe-
 
Table 3
 
Costs and frequencies used in the model
 
Cost parameter Base case value (range $) Reference for range
Bilirubin/uric acid 7 (4–11) Third-party database
Blood Center, first hour 57 (31–84 ) Third-party database
Blood Center, each additional hour 47 (3–101) Third-party database
Complete blood count 7 (3–12) Third-party database
Clinic visit, moderately complex 55 (29–81) Third-party database
Clinic visit, simple 24 (10–37) Third-party database
Epoetin 6,500 units/ three times weekly 199 (178–306) 37 (38)
Epoetin (by varying cost) (3,000 units–10,000 units, TIW) 199 (91–360) 37 (14–17)
Hemogram 6 (3–9) Third-party database
Reticulocytes 9 (5–12) Third-party database
Transfusion 178 (89–356) PSBC and UWMC
Frequency/Count Parameter in Combination Therapy Arm Frequency (range) Reference
Frequency of laboratory draw—bilirubin/ Uric acid 6–7 (3–14) 9–10,11
Frequency of laboratory draw—complete blood count 3 (1– 6) 9–10,11
Frequency of laboratory draw—hemogram 4–5 (2–10) 9–10,11
Frequency of laboratory draw—reticulocytes 3–12 (no change) 9–10,11
Frequency of clinic visit, moderately complex 5 (3–10) 9–10,11
Frequency of clinic visit, simple 3–6 (2–12) 9–10,11
Frequency of transfusion 1–2 (1–4) CJ
Count, Blood Center, first hour 1 (no change) CJ
Count, Blood Center, additional hours 4 (2–6) CJ
Duration of epoetin therapy (weeks) 6 (6–12) AHFS
Number of hours, Blood Center 4 (2–6) Third-party database
 
AHFS, AHFS ’99 Drug Information, American Society of Health-System Pharmacists, Bethesda, MD, 1999; CJ, clinical judgment; PSBC, Puget Sound Blood Center;
TIW, three times weekly; UWMC, University of Washington Medical Center.
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tin and transfusions was more frequent in this
group of patients than in any other.
We also explored two additional, clinically plau-
sible scenarios. In the first scenario, we modeled a
ribavirin dose of 800 mg/day to reflect the possi-
bility that if a lower dose of ribavirin were used
(800 mg/day vs. 1000–1200 mg/day) the incidence
of RIHA may be reduced. We adjusted the cost of
ribavirin to 800 mg/day and varied the incidence
of mild hemolytic anemia from 41% to 72% (an
increase of 75%), moderate from 37% to 19% (a
decrease of 50%), and severe from 22% to 11%
(a decrease of 50%). Importantly, the clinical and
economic impacts of a potential reduction in effi-
cacy due to discontinuation of combination ther-
apy is not easily estimated and thus were not in-
cluded in the scenario.
To assess the impact of greater use of epoetin
therapy, we modeled a scenario that included data
from the studies in which patients had received an
OLT and transfusions or epoetin. This scenario used
the percentage of transfusions (6.7%) and epoetin
(11%) found in the OLT trials [14–16], but used the
probabilities of clinical significance and severity found
in the base case.
 
Results
 
Literature Review
 
Twenty-six articles met the inclusion criteria and
were categorized into seven distinct groupings of
trials [9–11,14–36]. These provided the incidence
and treatment data used in the analysis (Table 1).
The first six articles comprise a group of early
studies that explored the use of ribavirin as single-
agent therapy in the treatment of CHC [18–23].
 
They are a mix of pilot studies and randomized,
placebo-controlled trials that used a dose of rib-
avirin of at least 1000 mg/day during the treatment
course. Seven additional studies, enrolling fewer
than 50 patients each and using combination ther-
apy with interferon 
 

 
-2b and ribavirin, comprise
the second group [24–30]. A third group of studies
consists of patients who had undergone OLT [14–
16]. Recurrent hepatitis C after OLT can be more
aggressive, leading to graft loss, recurrent cirrho-
sis, and subsequent liver failure [14]. A fourth group
is comprised of a single abstract in which the au-
thors used epoetin to reduce morbidity associated
with RIHA [17]. The fifth group consists of larger
(greater than 50 patients each) randomized, con-
trolled trials evaluating combination therapy [31–
35]. A sixth group consists of one meta-analysis of
individual patient data from four European cen-
ters [36]. Finally, the phase III approval trials
comprise the seventh group [9–11].
 
Base Case
 
The base case analysis reflects the difference be-
tween the direct cost of treating clinically signifi-
cant RIHA ($303) and the direct cost of routine mon-
itoring for nonclinically significant RIHA ($133) for
one patient over a 48-week course of treatment. The
attributable difference was $170 per patient per treat-
ment course. These results are listed in Table 4.
 
Sensitivity Analyses
 
We conducted a series of one-way sensitivity anal-
yses on all parameters and grouped the results ac-
cording to the type of parameter varied: probabil-
ity, cost, or frequency. In the cost category, the lowest
and highest costs, $77 and $177, respectively, oc-
 
Table 4
 
Results: direct costs of treating ribavirin-induced hemolytic anemia
 
Cost of treating clinically 
significant RIHA ($)
Cost of monitoring for not 
clinically significant RIHA ($)
Incremental cost difference (attributable 
to clinically significant) RIHA ($)
Base case 303 133 170
Sensitivity analyses, one way
Probability parameters
Probability of developing clinically 
significant hemolytic anemia
190–310 133 57–177
Probability of receiving epoetin 258–330 133 125–197
Cost parameters
Cost, clinic visit, simple 210–310 133 77–177
Frequency parameters
Frequency: clinic visit, simple 
complexity (baseline 3–6 visits)
210–450 133 77–317
Best case 142 74 68
Worst case 884 192 692
Additional, clinically plausible scenarios
800-mg case 282 133 149
Orthotopic liver transplant case 417 133 284
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curred in the analysis where the cost of a simple
clinic visit was varied between the lower and up-
per boundaries of the $10 to $37 range (baseline
$24). Similarly, the frequency of simple clinic vis-
its revealed the greatest cost variation in the fre-
quency category: $77 to $317. This occurred when
the frequency of simple clinic visits was varied
from 2 to 12 visits (baseline 3 to 6 visits). Finally,
in the category in which probabilities were varied,
the possibility of developing clinically significant
hemolytic anemia while receiving combination ther-
apy was the parameter that resulted in the lowest
cost, $57. This parameter was varied from the lower
boundary of 0.37 to the upper boundary of 1.0
(base case 
 

 
 0.74). The highest cost in the probabil-
ity category was $197, and occurred when the prob-
ability of receiving epoetin therapy was varied from
0% to 11%.
The best- and worst-case scenarios showed an
attributable cost difference of $68 and $692 per
treatment course, respectively.
The results of the case wherein a reduced dose
of 800 mg/day of ribavirin was used resulted in a
cost of treating hemolytic anemia of $149, a $21
(12%) reduction from the base case. This is the re-
sult of changes in two factors: the lower cost of
800 mg/day when compared with 1000 to 1200
mg/day of ribavirin, and the decreased incidence
of RIHA when this lower dose is used.
Last, we modeled the scenario based on the per-
centage of epoetin used in the OLT trials. Because
transfusions were used 6.7% of the time and epoe-
tin was used 11% of the time in this scenario, the
cost of treating RIHA increased from $170 to
$284 per patient, or 67% [14–16].
 
Discussion
 
The use of combination interferon 
 

 
-2b/ribavirin
therapy for the treatment of CHC results in an in-
cidence of RIHA, defined as a reduction in hemo-
globin to less than 100 g/L, of approximately 7%
to 9% [9–11]. The mean maximum drop in hemo-
globin is between 29 and 31 g/L in phase III trials
[9–12]. In the base case, the cost of managing clin-
ically significant RIHA was $170 per patient per
48-week treatment course. In comparison, the di-
rect drug cost of a 48-week treatment course of
combination therapy with interferon 
 

 
-2b/ribavi-
rin is approximately $16,459, while for a 48-week
treatment course of interferon 
 

 
-2b monotherapy,
the direct drug cost is $5,460 [37]. Thus, the di-
rect cost of managing RIHA comprises 1% or 3%
of the cost of combination therapy or monother-
 
apy, respectively. It does not increase costs signifi-
cantly. To the best of our knowledge, no one else
has systematically estimated the direct cost of
managing RIHA in this patient population.
It is important to remember that this number
reflects only the direct cost of medical manage-
ment. Because management of RIHA can include
ribavirin dosage reduction early in the treatment
course, there is a potential for reduction in effi-
cacy for patients who complete the course of ther-
apy with a reduced dose of ribavirin. Whether this
decrease in dose decreases efficacy is controver-
sial. In a population previously resistant to inter-
feron 
 

 
-2b monotherapy, Salmeron et al. [40] re-
cently compared the effectiveness of interferon
 

 
-2b/ribavirin 600 mg/day with interferon 
 

 
-2b
monotherapy. They found the combination no more
effective than interferon 
 

 
-2b alone. In contrast,
Bonkovsky et al. [41] studied a similar population
and found a 600-mg daily dose of ribavirin to be at
least as effective as a 1000- to 1200-mg daily dose
of ribavirin when given in combination with inter-
feron 
 

 
-2b for CHC.
Similarly, early discontinuation of ribavirin po-
tentially causes a reduction in efficacy, resulting in
a rate similar to that observed in patients receiving
interferon 
 

 
-2b monotherapy. Wong et al. [42,43]
have found that combination therapy with inter-
feron 
 

 
-2b/ribavirin is cost-effective when com-
pared with interferon 
 

 
-2b monotherapy, in both
initial treatment and relapse. Equally as pertinent
however, is the work of Younossi et al. [44], which
demonstrated the cost-effectiveness of interferon
 

 
-2b monotherapy over no therapy. In our work,
if we assume that patients in whom ribavirin is dis-
continued complete their course of therapy with
interferon 
 

 
-2b, cost-effectiveness is maintained.
We addressed the uncertainty in our model by
conducting one-way sensitivity analyses on all pa-
rameters, including the cost and frequency of sim-
ple clinic visits and the probability of developing
clinically significant RIHA. Variations in the cost
and frequency of simple clinic visits resulted in a
cost difference ranging from $77 to $317 per treat-
ment course. Because the progress of patients re-
ceiving combination therapy for CHC is frequently
monitored through follow-up simple clinic visits, a
reduction or increase in the cost or frequency of
these visits would impact significantly on the model.
Decreasing the probability of developing clinically
significant RIHA resulted in the lowest cost when
this factor was analyzed independently ($57). Be-
cause the percentage of patients experiencing clini-
cally significant RIHA drives all other costs, reducing
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this probability by 50% (from 74% to 37%) logi-
cally results in the lowest cost of treatment of this
adverse effect. However, when these specific pa-
rameters are varied in combination, the outcome
is a range of costs between $57 and $317. Al-
though the baseline cost was not high, the uncer-
tainty was relatively high. This reflects the vari-
ability in the frequency and cost of resources used
in the management of RIHA.
Our analysis also has implications for using the
reduced dose (800 mg/day) of ribavirin. The 800-
mg/day dose is important because dose-finding stud-
ies were not published prior to initiation of the
phase III trials, and the dose of ribavirin that min-
imizes the risk-benefit ratio has not yet been
firmly established. It is possible that the 800-mg
dose may have the same efficacy as higher doses.
Studies are currently under way to address this is-
sue [41,45]. Should future data demonstrate that
800 mg/day is the optimal dose of ribavirin, the
direct cost of treating RIHA will be reduced in our
model from $170 to $149 per patient.
Some authors, especially those working with
the OLT population, have evaluated the use of
epoetin to manage and overcome RIHA. The OLT
population is distinct from the population in the
phase III approval trials in that it has recurrent,
and possibly more refractory, CHC. In this popu-
lation, the use of epoetin may be more important
in overcoming RIHA. We included the OLT popu-
lation only in the sensitivity analysis. Using the data
to model this strategy, we found this increased the
direct cost to $284 per patient per treatment course.
This large variation occurs because epoetin therapy
is relatively expensive ($199 per week for a 6-
week treatment course). Still, when compared
with the direct drug cost of a 48-week treatment
course of combination therapy, $284 does not add
significantly to drug costs.
 
Limitations
 
We recognize that our analysis is limited in some
respects. There were uncertainties in some of the
probability estimates, even though the majority of
these were derived from the literature. The clinical
data set was limited by the lack of a uniform trial
design, lack of a consistent definition for hemoly-
sis, and missing data on both the percentage of pa-
tients experiencing hemolysis and the mean reduc-
tion in hemoglobin concentration. Despite this, we
were able to catalog the percentage of patients in
whom the ribavirin dose was reduced, the percent-
age of patients in whom ribavirin was discon-
tinued, and the percentage of patients in whom
hemolytic anemia was treated with packed red
blood cell transfusions or epoetin. This informa-
tion was sufficient to provide us with reference
points to establish a parametric model. Because of
these limitations in the data set, we used only the
data from the Phase III pivotal trials, on which the
US approval of the drug regimen was based, to
populate the base case [9–11]. Parameters from
the additional studies were used in the best- and
worst-case sensitivity analyses, as well as in the
analyses modeling the 800-mg dose of ribavirin
and the OLT model [14–36].
In the OLT scenario, we included a 6- to 12-
week treatment course for epoetin. This yields a
conservative cost estimate, because there is the po-
tential to continue the use of epoetin beyond this
time frame in an effort to overcome the RIHA and
continue ribavirin concomitantly with epoetin for
the duration of the treatment course.
Generalizations that can be made from our
work are limited. The cost of treating potential
morbidity caused by hemolytic anemia, including
deterioration of cardiac function or exacerbation
of the symptoms of coronary artery disease, was
also considered in the model. In his summary of
the phase III trials, Maddrey described a mean de-
crease in hemoglobin and an exacerbation of car-
diac events in only nine patients receiving combi-
nation therapy with interferon 
 

 
-2b and ribavirin
[12]. This constitutes less than 1% of the patients
in the combination therapy arm. It was not possi-
ble to definitively determine whether combination
therapy was associated with the exacerbation of
cardiac symptoms more than was monotherapy
with interferon-alpha [12]. However, the incidence
of underlying comorbidities in a community-based
population may be different from that in a con-
trolled clinical trial. In their study of community-
based patients, Lyons et al. [46] found that 50% of
the patients required a dose reduction of ribavirin
due to thrombocytopenia, leukopenia, and/or ane-
mia. An adverse-effect profile this significant, es-
pecially in those with underlying comorbidities,
would incur a significantly greater toll on both
morbidity and medical costs.
 
Conclusion
 
Combination therapy with interferon 
 

 
-2b/ribavi-
rin has become the standard of care in the treat-
ment of CHC, and the importance of managing
the dose-limiting adverse effect of RIHA is now a
clinical concern. We estimated the direct medical
cost of treating RIHA in a controlled clinical trial
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population to be low—$170 per patient per 48-
week treatment course, or about 1% of annual drug
treatment costs of combination therapy. Cost-effec-
tiveness is maintained even if discontinuation of
ribavirin is required due to RIHA, requiring com-
pletion of a treatment course with interferon 
 

 
-2b
monotherapy. Questions remain about the optimal
dose of ribavirin and the incidence of RIHA in a real-
world population with underlying comorbidities. De-
spite these uncertainties, this initial evaluation of the
direct cost of treating RIHA in a controlled popula-
tion sheds light on the clinical and economic implica-
tions and offers useful strategies for managing this
clinically important adverse effect.
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